血红素氧合酶是血红素降解的起始酶和限速酶。在糖尿病及糖尿病心血管并发症、糖尿病肾病和糖尿病视网膜病变的发展过程中多种组织细胞血红素氧合酶的表达水平发生了改变,而应用血红素氧合酶的抑制剂、诱导剂或基因干扰技术人为改变血红素氧合酶表达的水平可以加速或延缓该病程进展。提示血红素氧合酶做为糖尿病病情诊断和治疗的手段有一定临床应用前景。 Heme oxygenase is the initial enzyme and rate-limiting enzyme for heme degradation. In the development of diabetic and diabetic cardiovascular complications, diabetic nephropathy and diabetic retinopathy, the expression levels of heme oxygenase in various tissue cells have been changed. However, the application of heme oxygenase inhibitors, inducers or genes Interfere with artificially altering the level of heme oxygenase expression can accelerate or delay the progression of the disease. Prompt heme oxygenase as a means of diagnosis and treatment of diabetes have some clinical application prospects.